Keyphrases
Bacillus Calmette
100%
Vaccination
86%
Hospitalization
85%
Randomized Clinical Trial
80%
Respiratory Syncytial Virus Hospitalization
80%
At Birth
75%
Respiratory Syncytial Virus
60%
Asthma
50%
Atopic Dermatitis
50%
Virus-neutralizing Antibody
50%
Incidence Rate
33%
Respiratory Syncytial Virus Infection
32%
Cytokine Response
30%
Population-based Cohort Study
27%
Causal Direction
25%
Immunization
25%
Cord Blood
25%
Risk Factors
25%
Palivizumab
25%
Prospective Randomized Clinical Trial
25%
Telephone Consultation
25%
Mixed Methods Design
25%
Seasonal Variation
25%
Multicenter Trial
25%
Vietnam
25%
Informational Needs
25%
Bloodstream Infection
25%
Child with Heart Disease
25%
Allergic Rhinoconjunctivitis
25%
Newborn Infant
25%
Recurrent Wheeze
25%
External Data
25%
Prescription Registry
25%
Confidence Interval
18%
Non-specific Effects
16%
Gestational Age
16%
Hospitalization Risk
15%
Denmark
15%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
84%
Cohort Study
75%
Human respiratory syncytial virus
64%
Respiratory Syncytial Virus Infection
56%
Infection
39%
Bloodstream Infection
25%
Atopic Dermatitis
25%
Palivizumab
25%
Twin Study
25%
Observational Study
25%
Randomized Clinical Trial
25%
Heart Disease
25%
Disease Predisposition
18%
Medicine and Dentistry
Randomized Clinical Trial
75%
Cohort Analysis
50%
Infection
47%
In Vitro
33%
Cytokine Response
33%
Human respiratory syncytial virus
26%
Asthma
25%
Pediatrics
25%
Palivizumab
25%
Atopic Dermatitis
25%
Bloodstream Infection
25%
Observational Study
25%
Cytokine Production
25%
Hazard Ratio
21%
Disease Predisposition
18%
Thymus
16%